NCT05533905Completed
DECISIve - DiagnosE Using the Central veIn SIgn v1.0
DECISIve - DiagnosE Using the Central veIn SIgn. A Prospective Diagnostic Superiority Study Comparing T2*MRI and Lumbar Puncture in Patients Presenting With Possible Multiple Sclerosis.
Source: ClinicalTrials.gov · Last updated 29 Mar 2024
Brief summary (registry, in English)
DECISIve - DiagnosE using the Central veIn SIgn. A prospective diagnostic superiority study comparing T2\* MRI and lumbar puncture in patients presenting with possible Multiple Sclerosis
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 113 (actual)
- First submitted
- 6 Sept 2022
- Start date
- 9 Dec 2019
- Primary completion date
- 6 Nov 2023
- Lead sponsor
- Nottingham University Hospitals NHS Trust
- Diseases
- Multiple sclerosis
- NCT number
- NCT05533905
What you commit to
- Study type: Observational
- Participants enrolled: 113
- From 9 Dec 2019 to the primary completion date, 6 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication or inability to undergo MRI due to metal or metal implants, pregnancy, claustrophobia, pain, spasticity, or excessive movement related to tremor.
Other illness
- Unwilling or unable to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that, in the opinion of the PI, is likely to affect the participant's ability to comply with the study protocol.
- Acute COVID-19 infection at time of face-to-face interactions during study (unless investigations can be delayed until considered safe by the responsible clinician and PI) either diagnosed clinically or by acute infection testing
- Participant required to self-isolate at time of face-to-face interactions during study (unless investigations can be delayed until considered safe by the responsible clinician and PI) due to COVID-19 exposure, shielding due to medical advice, public health advice or governmental advice/laws.
Other
- Fulfils the diagnosis of MS, as defined by the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2017).
- Unable to provide informed consent.
Who the study is looking for
- Presentation with a typical clinically isolated syndrome (Thompson et al. 2017) for diagnostic evaluation of MS.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NUH NHS Trust Coordinator of this site? Confirm its status | Nottingham | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.